



Iovance Biotherapeutics Lawsuit Alert: Johnson Fistel Announces Shareholders with Losses Should Contact the Law Firm

SAN DIEGO, CA, UNITED STATES, June 11, 2025 /EINPresswire.com/ --

Shareholder rights law firm Johnson Fistel, PLLP announces that a class action lawsuit has commenced on behalf of investors of [Iovance Biotherapeutics, Inc.](#) (NASDAQ: IOVA).



If you incurred significant losses and want to act as the lead plaintiff in the class action lawsuit or determine if you are eligible to receive a potential recovery of your losses, please submit your details here: <https://www.johnsonfistel.com/investigations/iovance-biotherapeutics-inc>

CLASS PERIOD: May 9, 2024, through May 8, 2025

LEAD PLAINTIFF DEADLINE: July 14, 2025

DOCKET #: 25-CV-04177 (N.D. California)

ALLEGATIONS: False and/or misleading statements

Contact for More Information: James Baker, (619) 814-4471, jimb@johnsonfistel.com or fjohnson@johnsonfistel.com

The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information about Iovance's business, operations, and prospects, including allegations that: (1) new Authorized Treatment Centers ("ATCs") were experiencing longer timelines to begin treating patients with Amtagvi; (2) Iovance's sales team and new ATCs were ineffective in patient identification and patient selection for Amtagvi, leading to higher patient drop-offs; and (3) the foregoing dynamics led to higher costs and lower revenue because ATCs could not keep pace with manufactured product.

If you purchased shares and experienced losses, and would like to learn more about serving as lead plaintiff, please contact Jim Baker at 619-814-4471 or jimb@johnsonfistel.com. Please include your name and contact information. To learn more about the lead plaintiff process, visit: <https://www.johnsonfistel.com/lead-plaintiff-deadlines>

About Johnson Fistel, PLLP | Top Law Firm, Securities Fraud, Investors Rights:

Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, Colorado, and Idaho. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. We also extend our services to foreign investors who have purchased on US exchanges. Stay updated with news on stock drops and learn how Johnson Fistel, PLLP can help you recover your losses. For more information about the firm and its attorneys, please visit

<http://www.johnsonfistel.com>.

Achievements:

In 2024, Johnson Fistel was honored to be ranked in the Top 10 Plaintiff Law Firms by the ISS Securities Class Action Services. This recognition underscores our effectiveness in advocating for investors, having recovered approximately \$90,725,000 for aggrieved clients in cases where we served as lead or co-lead counsel. This notable accomplishment marks the eighth occasion our firm has been recognized as a top plaintiffs' securities law firm in the United States, as determined by the total dollar value of final recoveries.

Attorney advertising.

Past results do not guarantee future outcomes.

Services may be performed by attorneys in any of our offices.

Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.

Contact:

Johnson Fistel, PLLP

501 W. Broadway, Suite 800, San Diego, CA 92101

James Baker, Investor Relations or Frank J. Johnson, Esq., (619) 814-4471

jimb@johnsonfistel.com or fjohnson@johnsonfistel.com

Johnson Fistel, PLLP

Johnson Fistel

+1 619-814-4471

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/821129443>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.